Literature DB >> 16075861

Peritonsillar abscess: a comparison of outpatient i.m. clindamycin and inpatient i.v. ampicillin/sulbactam following needle aspiration.

Cem Ozbek1, Erdinc Aygenc, Evrim Unsal, Cafer Ozdem.   

Abstract

In an attempt to assess the effect of antibiotic choice on the treatment of peritonsillar abscess, we compared the clinical efficacy of empiric intramuscular clindamycin and intravenous ampicillin/sulbactam (following needle aspiration of the abscess) in a prospective, randomized study of 58 patients. Patients in the clindamycin group were treated on an outpatient basis, whereas those in the ampicillin/sulbactam group were hospitalized for the duration of their treatment (minimum: 7 days). Comparison of clinical outcomes with respect to the posttherapeutic duration of fever and throat pain and the time to resumption of eating revealed no statistically significant difference between the two groups. These results suggest that intramuscular clindamycin is an excellent choice and can be safely prescribed on an outpatient basis following needle aspiration, thereby reducing both antibiotic and hospital costs.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16075861

Source DB:  PubMed          Journal:  Ear Nose Throat J        ISSN: 0145-5613            Impact factor:   1.697


  3 in total

1.  Medical and surgical treatment of peritonsillar, retropharyngeal, and parapharyngeal abscesses.

Authors:  Fred S Herzon; Angela D Martin
Journal:  Curr Infect Dis Rep       Date:  2006-05       Impact factor: 3.725

2.  Gram staining for the treatment of peritonsillar abscess.

Authors:  Yukinori Takenaka; Kazuya Takeda; Tadashi Yoshii; Michiko Hashimoto; Hidenori Inohara
Journal:  Int J Otolaryngol       Date:  2012-02-20

3.  High Risk of Peritonsillar Abscess in End-Stage Renal Disease Patients: A Nationwide Real-World Cohort Study.

Authors:  Geng-He Chang; Ang Lu; Yao-Hsu Yang; Chia-Yen Liu; Pey-Jium Chang; Chuan-Pin Lee; Yao-Te Tsai; Cheng-Ming Hsu; Ching-Yuan Wu; Wei-Tai Shih; Ming-Shao Tsai
Journal:  Int J Environ Res Public Health       Date:  2021-06-24       Impact factor: 3.390

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.